Abstract
In 1969, Vaughan Williams proposed a classification for antiarrhythmic drugs at an international meeting of cardiologists and electrophysiologists in Elsinor, Denmark (Vaughan Williams 1970). The majority of the antiarrhythmic agents, then and now, restrict the fast inward sodium current. However, distinct differences within this class I action have necessitated subdivision of class I drugs into a, b, and c groups. The most distinctive characteristic of the Ic agents is that then bind slowly and dissociate slowly from the Na channel (Campbell and Vaughan Williams 1983). Thus, during tachycardias, not enough time will elapse between beats to permit the drug to dissociate from the Na channel, causing a population of channels to be “blocked” and thus slowing conduction markedly (Vaughan Williams 1984). These cellular electrophysiologic characteristics of the class Ic agents provide a rationale for both their potency and possible disadvantages. By binding to Na channels and remaining bound throughout the cardiac cycles at fast (though physiologic) heart rates, the drugs will decrease ectopy, the trigger for initiating ventricular tachycardia. Conduction will be slowed and the substrate critical for sustained ventricular tachycardia (VT) leading to sudden death may be favorably modified. The same electrophysiologic actions, however, in patients with an already diseased conducting system could delay conduction to the point of impairment with asystole, requiring insertion of a pacemaker.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abdollah H, Brugada P, Green M, Wehr M, Wellens H (1984) Clinical efficacy and electrophysiologic effects of intravenous and oral encainide in patients with accessory atrio-ventricular pathways and supraventricular arrhythmias. Am J Cardiol 54 (6): 544–549
Almotrefi AA, Baker JB (1981) Antifibrillatory efficacy of encainide, lorcainide, and ORG6OOI compared with lignocaine in isolated hearts of rabbits and guinea pigs. Br J Pharmacol 73: 373–377
Anderson J, Anastasiou-Nana M, Lutz J., Writer S (1985) Comparison of intravenous lorcainide with lidocaine for acute therapy of complex ventricular arrhythmias. Results of randomized study with cross-over option. J Am Coll Cardiol 5: 333–341
Anderson J, Lutz J, Allison S (1983) Electrophysiologic and antiarrhythmic effects of oral flecainide in patients with inducible ventricular tachycardia. J Am Coll Cardiol 2: 105–114
Anderson J, Stuart J, Perry B, Hamersveld D, Johnson T, Conard G, Chang S, Kvam D, Pitt B (1981) Oral flecainide acetate for the treatment of ventricular arrhythmias. N Engl J Med 305: 473–477
Antonaccio M, Verjee S (1986) Dosing recommendations for encainide. Am J Cardiol 58: 114–116c
Baedeker W, Wirtzfeld A, Sack D, Obersohl K (1977) The antiarrhythmic effect of pro-pafenone in ventricular tachycardia. Herz/Kreisl 9: 348–352
Baker BJ, Dinh H, Kroskey D, deSoyza N, Murphy M, Franciosa J (1984) Effect of propafenone on left ventricular ejection fraction. Am J Cardiol 54: 20–22d.
Bannitt EH, Bronn WR, Coyne WE et al. (1977) Antiarrhythmics. 2. Synthesis and antiarrhythmic activity of AHpiperidylalkyl) trifluoroethoxybenzamides. J Med Chem 20: 821–826
Bar F, Farre J, Ross D, Vanagt E, Gorgels A, Wellens H (1981) Electrophysiological ef-fects of lorcainide, a new antiarrhythmic drug. Br Heart J 45: 292–298
Bajaj A, Woosley R, Roden D (1986) Acute reversal of Odemethyl encainade induced conduction slowing. J Am Coll Cardiol 7 (Suppl 2): 82a
Beck OA, Hochrein H (1978) Indications and risks of antiarrhythmic treatment with propafenone. Dtsch Med Wochenschr 103: 1261–1265
Bergstrand R, Wang T, Roden D, Avant G, Sutton W, Siddoway L, Wolfenden H, Woosley R, Wilkinson G, Wood A (1986 a) Encainide disposition of patients with chronic cirrhosis. Clin Pharmacol Ther 40: 148–154
Bergstrand R, Wang T, Roden D, Stone W, Wolfenden H, Woosley R, Wilkinson G, Wood A (1986) Encainide disposition in patients with renal failure. Clin Pharmacol Ther 40: 64–70
Bernard R, Renard M, Shita A, de-Hemptinne J, Gillet J, Lewinson H, Liebens I, Waterschoot P (1986) Hemodynamic repercussions and clinical tolerance of six Class I antiarrhythmic agents after acute myocardial infarction. Ann Cardiol Angeiol (Paris) 35 (4): 195–198
Bhamra RK, Flanagan RJ, Holt DW (1984) High performance liquid chromatographic method for the measurement of mexiletine and flecainide in blood plasma or serum. J Chromatogr 307: 439–444.
Blevins R, Kerin N, Mathias P, Pesola D, Faitel K, Jarandilla R, Garfinkel C, Ruben- fire M (1986) Intravenous lorcainide versus lidocaine in the treatment of frequent and complex ventricular arrhythmias. Am Heart J 111: 447–451
Borchard U, Boisten M (1982) Effect of flecainide on action potentials in alternating current-induced arrhythmias in mammalian myocardium. J Cardiovasc Pharmacol 4: 205–212
Borgeat A, Goy JJ, Maendly R, Kaufmann U, Grbic M, Sigwart U (1986) Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 58 (6): 496–498
Breithardt G, Borggrefe M, Wiebringhaus E, Seipel LA (1984) Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long term follow up. Am J Cardiol 54: 29–39D
Brembilla-Perrot B, Admant P, Le-Helloco A, Pernot C (1985) Loss of efficacy of flecainide in the Wolff-Parkinson-White syndrome after isoproterenol administration. Eur Heart J 6 (12): 1074–1078
Bren G, Varghese PJ, Katzs R, Roth A (1981) Arrhythmogenicity of encainide, the role of QT interval. Am J Cardiol 47: 498
Brodsky Ma, Allen BJ (1985) Propafenone. Chest 88 (2): 164–165
Brugada, P, Abdollah H, Hein JJ, Wellens H (1984) Suppression of incessant supraventricular tachycardia by intravenous and oral encainide. J Am Coll Cardiol 4 (6): 1255–1260
Brutsaert D (1981) Effect of encainide on myocardial contractility of cat papillary muscle. Eur J Pharamacol 76: 267–269.
Byrne JE, Gomoll AW (1982) Antiarrhythmic action of encainide versus ventricular arrhythmias in the conscious dog following coronary artery ligation. Can J Physiol Pharmacol 60: 369–375
Byrne J, Gomoll A, McKinney G (1977) Antiarrhythmic properties of MJ9067 in acute animal models. J Pharmacol Exp Ther 200 (1): 147–154
Camm A (1984) Cardiac electrophysiology of four new antiarrhythmic drugs: encainide, flecainide, lorcainide and tocainide. Eur Heart J 5 (Suppl b): 75–79
Camm A, Hellsterand K, Nathan A, Bexton R (1985) Clinical usefulness of flecainide acetate in the treatment of paroxysmal supraventricular arrhythmias. Drugs 29 (Suppl 4): 7–13
Campbell TJ (1983) Importance of physiochemical properties in determining the kinetics of the effects of Class I antiarrhythmic drugs on maximum rate of depolarization in guinea pig ventricle. Br J Pharmacol 80: 33–40
Campbell TJ, Vaughan Williams M (1983) Voltage and time dependent depression of maximum rate of depolarization of guinea pig ventricular action potentials by two antiarrhythmic drugs, flecainide and lorcainide. Cardiovasc Res 17: 251–258
Cardiac Arrhythmia Pilot Study (1986) Pro-arrhythmic and other adverse effects of encainide, flecainide, imipramine, moricizine, and placebo observed in the cardiac arrhythmia pilot study (abstr.) Circulation 74 (Suppl II): 313
Carmeliet E (1980) Electrophysiologic effects of encainide on isolated cardiac muscle and Purkinje fibers and on the Langendorff perfused guinea pig heart. Eur J Pharmacol 61: 247–262
Carmeliet E, Zaman MY (1979) Comparative effects of lighocaine and lorcainide on conduction in the Langendorff-perfused guinea pig heart. Cardiovasc Res 13: 439–449
Carmeliet E, Janssen P, Marsboom R, Van Nueten JM, Xhonneux R (1978) Antiar-rhythmic electrophysiologic and hemodynamic effects of lorcainide. Arch Int Pharmacodyn 231: 104–130
Cassagneau B, Miquel J, Puel J, Mordant B, Kher A, Fauvel J, Bounhoure J (1985) Antiarrhythmic and electrophysiological effects of encainide in supraventricular tachyarrhythmias. Arch Mai Coeur 78: 113–119
Chang SF, Miller AM, Fox JM, Welscher TM (1984) Application of a bonded phase extraction column for rapid sample preparation of flecainide from human plasma for high performance liquid chromatographic analysis, fluorescence or ultraviolet detection. Ther Drug Monit 6: 105–111
Chesnie B, Podrid P, Lown B, Raeder E (1983) Encainide for refractory ventricular tachyarrhythmia. Am J Cardiol 52: 495–500
Chesnie B, Lampert S, Podrid P, Lown B (1984) Lorcainide in patients with refractory ventricular tachyarrhythmias. J Am Coll Cardiol 3 (6): 1531–1539
Chilson D, Heger J, Zipes D, Browne K, Prystowsky E (1985) Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia. J Am Coll Cardiol 5: 1407–1413
Chimienti M, Salerno J, Moize M, Klersy C, Marangoni E, Previtali M, Bianchi P, Montemartini C, Bobba P (1985) Intravenous and oral encainide, electrophysiologic effects in patients with paroxysmal reciprocating supraventricular tachycardia. G Ital Cardiol 15 (5): 553–542
Cocco G, Strozzi C (1978) Initial clinical experience of lorcainide (R013-1042), a new antiarrhythmic agent. Eur J Clin Pharmacol 14: 105–109
Conard G, Jernberg MJ, Carlson GL, Ober RE (1975) Metabolism of R-818, an antiarrhythmic candidate in rats. Pharmacologist 17: 194
Conard GJ, Carlson GL, Frost JW, Ober RE (1979) Human plasma pharmacokinetics of flecainide acetate (R-818), a new antiarryhthmic, following single oral and intravenous doses (abstr.). Clin Pharmacol Ther 25: 218
Connolly S, Kates R, Lebsack C, Harrison D, Winkle R (1983) Clinical pharmacology of propafenone, Circulation 68: 589–596
Connolly S, Leback C, Winkle R, Harrison D, Kates R (1984) Propaferone disposition kinetics in cardiac arrhythmia. Clin Pharmacol Ther 36 (2): 163–168
Coumel P, Leclerq J, Assayag P (1984) European experience, with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. Am J Cardiol 54 (9): 60–66D
Cowan JC, Vaughan Williams EM (1981) Characterization of a new oral antiarrhythmic drug, flecainide. Eur J Pharmacol 73: 333–342
Dawson A, Roden D, Duff H, Woosley R, Smith R (1984) Differential effects of O-de- methyl encainide on induced and spontaneous arrhythmias in the conscious dog. Am J Cardiol 54: 654–658
Dennis P, Vaughan Williams EM (1985) Effects on rabbit cardiac potentials of aprin- dine, and indecainide, a new antiarrhythmic agent, in normoxia and hypoxia. Br J Pharmacol 85 (1): 11–19
Dennis P, Vaughan Williams EM (1986) The effects of indecainide, a new antidysrhyth-mic drug on nodal tissue on the isolated rabbit heart. J Cardiovasc Pharmacol 8(l):l–5
DeClerck F, van Gorp L, Xhonneux R (1978) Effects of lorcainide, a new antiarrhythmic compound, on the changes in heart rhythm induced by intravenous injection of adenosine 5-diphosphate in rats. Arch Int Pharmacodyn Ther 231: 222–231
DiBianco R, Fletcher D, Cohen A, Gottdieher JS, Singh JN, Katz RJ, Bates HR, Saver- brunn B (1982) Treatment of frequent ventricular arrhythmias with encainide: assessment using serial ambulatory electrocartdiograms, intracardiac electrophysio- logc studies, treadmill exercise tests, and radionucleide cineangiographic studies. Circulation 65: 1134–1147
Distlerath L, Reilly P, Martin M, Davis G, Wilkinson G, Guengerich F (1985) Purification and characterization of the human liver cytochromes P450 involved in debri- soquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 260 (15): 9057–9067
Doherty J, Waxman H, Kienzle M, Cassidy D, Marchlinsky F, Buxton A, Josephson M (1984) Limited role of intravenous propafenone hydrochloride in the treatment of sustained ventricular tachycardia: electrophysiologic effects and results of programmed ventricular stimulation. J Am Coll Cardiol 4 (2): 378–381
Dresel P (1984) Effect of encainide and its two major metabolites on cardiac conduction. J Pharmacol Exp Ther 228: 180–186
Dressier F, Gravinghoff L, Grutte E, Jungst BK, Liersch R, Nomay H, Puis I, Rauten- burg HW, Schmaltz A, Schumacher G (1985) The treatment of arrhythmias in infants and children using propafenone. Monatsschr Kinderheilkd 133 (3): 154–157
Duff HJ, Roden DM, Maffucci R, Vesper B, Conard G, Higgins S, Oates J, Smith R, Woosley R (1981) Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. Am J Cardiol 48: 1133–1140
Duff H, Roden D, Dawson A, Oates J, Smith R, Woosley R (1982) Comparison of ef-fects of placebo and encainide on programmed electrical stimulation and ventricular arrhythmia frequency. Am J Cardiol 50: 305–311
Duff HJ, Dawson AK, Roden DM, Oates JA, Smith RF, Woosley RL (1983) Electrophysiologic actions of o-demeltyl encainide, an active metabolite. Circulation 68: 385–391
Duff H, Roden D, Carey E, Wang T, Primm R, Woosley R (1985) Spectrum of antiar-rhythmic response to encainide. Am J Cardiol 56: 887–891
Dukes I, Vaughan Williams EM (1984) The multiple modes of action of propafenone. Eur Heart J 5: 115–125
Dykstra SJ, Minielli J, Lawson J, Furguson H, Duncan K (1973) Lysergic acid and quinidine analogs (2-O-acylaminophenethyl) piperidines. J Med Chem 16 (9): 1015–1020
Echt D, Mitchell L, Kates R, Winkle R (1983) Comparison of the electrophysiologic effects of intravenous and oral lorcainide in patients with recurrent ventricular tachycardia. Circulation 68 (2): 392–399
Echt D, Shapiro M, Trusso J, Mason J, Winkle R (1985) Treatment with oral lorcainide in patients with sustained ventricular tachycardia and fibrillation. Am Heart J 109: 28–32
Elharrar V, Zipes D (1982) Effects of encainide and metabolites (MJ14030 and MJ9444) on canine cardiac Purkinje and ventricular fibers. J Pharmacol Exp Ther 220: 440–447
Falk RH, O’Brien J (1986) Lorcainide: a comparative trial with quinidine gluconate in patients with previously untreated ventricular arrhythmias. Chest 4: 537–540
Farid K, Fasola A (1984) The disposition and metabolism of C14 indecainide in man. Pharmacologist 26: 171
Farid NA, Fasola A, Nash J (1985) Liquid chromatographic determination of indecai- nide, a new antiarrhythmic drug and its metabolite, desisopropylindecainide in biologic samples. J Chromatogr 337 (2): 329–340
Fauchier J, Cosnay P, Rouesnel P, Moquet B, Bonnet P, Scala P, Demeyer J (1985) Ef: feet of oral and injectable flecainide in patients with accessory atrial ventricular pathway. Arch Mai Coeur 78: 81–90
Flecainide Quinidine Research Group (1983) Flecainide versus quinidine for treatment of chronic ventricular arrhythmias. A multicenter clinical trial. Circulation 67: 1117–1123
Flecainide Ventricular Tachycardia Study Group (1986) Treatment of resistant ventricular tachycardia with flecainide acetate. Am J Cardiol 57: 1299–1304
Flowers D, O’Gallagher D, Torres V, Miura D, Somberg JC (1985) Flecainide: long term treatment using a reduced dosing schedule. Am J Cardiol 55: 79–83
Furlanello F, Disertori M, Vergara G, Guarnerio M, Dal Forno P, Padrini R, Gobbato S, Ferrari M (1983) Clinical evaluation of new antiarrhythmic agents, an experience with proprafenone. Int J Clin Pharmacol Res 3 (2): 101–105
Furlanello F, Vergara G, Dal Forno P, Disertori M, Inama G (1984) Clinical experience with propafenone in paroxysmal supraventricular reciprocating tachycardia. G Ital Cardiol 14 (5): 379–380
Garcia-Civera R, Sanjuan R, Morell S, Ferrero J, Miralles L, Llavador J, Lopes-Merino V (1984) Effects of propafenone on induction and maintenance of atrioventricular nodal re-entrant tachycardia. PACE 7 (4): 649–655
Gibson J, Somani P, Bassett AL (1978) Electrophysiologic effects of encainide (MJ9067) on canine Purkinje fibers. Eur J Pharmacol 52: 161–169
Gomoll AW, Mayol RF (1982) Comparative hemodynamic effects of encainide and its two major metabolites in anesthetized dogs. Pharmacologist 24: 233
Gomoll AW, Byrne JE, Mayol RF (1981) Comparative antiarrhythmic and local anesthetic action of encainide and its two major metabolites (abstr). Pharmacologist 23: 209
Gomoll A, Byrne J, Antonnaccio M (1986) Electrophysiology, hemodynamic and antiarrhythmic efficacy model studies on encainide. Am J Cardiol 58: 10–17c
Goy J, Grbic M, Hurni M, Finci L, Maendly R, Due J, Sigwart U (1985) Conversion of supraventricular arrhythmias to sinus rhythm using flecainide. Eur Heart J 6 (6): 518–524
Gstottner CK, Gmeiner R (1979) Intracardiac electrophysiological effects of lorcainide in man. Eur J Clin Pharmacol 15: 241–247
Guehler J, Gornick C, Tobler G, Almquist A, Schmid J, Benson W, Benditt D (1985) Electrophysiological effects of flecainide acetate and its major metabolites in the canine heart. Am J Cardiol 55: 807–812
Guengerich F, Distelrath L, Reilly P, Wolff T, Shimada T, Umbenhauer DA, Martin M (1986) Human liver cytochromes P450 involved in polymorphism of drug oxidation. Xenobiotica 16 (5): 367–378
Hapke H, Prigge E (1976) Zur Pharmakologie von 2’-[2-hydroxy-3-(propylamino)-pro- poxy-3-phenylpropi (propafenon, Sa 79)-hydrochlorid. Arzneimittelforschung 26: 1849–1857
Hellestrand KJ, Bexton RS, Nathan AW, Spurrell RAJ, Camm AJ (1982) Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. Br Heart J 48: 140–148
Hellestrand K, Nathan A, Bexton R, Spurrell R, Camm AJ (1983) Cardiac electrophysiologic effects of flecainide acetate for paroxysmal reentrant junctional tachycardias. Am J Cardiol 51 (5): 770–776
Hoddess AB, Follansbee WP, Spear JF, Moore EN (1979) Electrophysiological effects of a new antiarrhythmic agent, flecainide, on the intact canine heart. J Cardiovasc Pharmacol 1: 427–439
Hodges M, Haugland JM, Granrud G, Conard CJ, Asinger RW, Mikell FL, Krejci J (1982) Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent. Circulation 65: 879–885
Hohnloser S, Zeiher A, Hust MH, Wollschlager H, Just H (1983) Flecainide induced aggravation of ventricular tachycardia. Clin Cardiol 6: 130–135
Holland D, Lacefield W (1983) LY135837: a potent new antiarrhythmic agent. Fed Proc 42: 1290
Hollmann M, Brode E, Holtz D, Kaumeiler S, Kehrhahn O (1983 a) Investigations on the pharmacokinetics of propafenone in man. Arzneimittelforschung 33: 763–770
Hollmann M, Hege H, Brode E, Buhler V, Holtz D, Kaumeier S, Kehrhahn O, Lietz H, Schwartz J, Stieren B, Weymann J ( 1983 b) Pharmacokinetic and metabolic studies of propafenone in volunteers. In: Schlepper M, Molsson B (eds) Cardiac arrhythmias. Proceedings of the first international rythmonorm congress. Springer, Berlin Heidelberg New York, pp 125–132
Hotzman JL, Berry DA, Kvam DC, Mottonen L, Borrell G (1984) Application of second order polynomial equation to the study of pharmacodynamic interactions: the effect of flecainide acetate and propranolol on cardiac output and vascular resistance. J Pharmacol Exp Ther 231: 286–290
Horowitz L (1986) Encainide in lethal ventricular arrhythmias evaluated by electrophysiologic testing and decrease in symptoms. Am J Cardiol 58: 83–86c
Horowitz L, Spielman S, Webb C, Morganroth J, Greenspan A (1985) The clinical electrophysiology of intravenous indecainide. Am Heart J 110: 784–788
Ikeda N, Davis L, Hauswirth O, Singh BN (1982) Flecainide: electrophysiologic profile in isolated cardiac muscle of an antiarrhythmic with different effects in ventricular muscle and Purkinje fibers (abstr). Circulation 66 (Suppl II): 379
Jackman W, Zipes D, Naccarelli G, Rinkenberger R, Heger J, Prystowsky E (1982) Electrophysiology of oral encainide. Am J Cardiol 49: 1270–1278
Jackson N, Verma SP, Frais MA, Silke B, Hafizullah M, Reynolds G, Taylor SH (1985) Hemodynamic dose response effects of flecainide in acute myocardial infarction, with and without left ventricular decompensation. Clin Pharmacol Ther 37: 619–624
Jahnchen E, Bechtold H, Kasper W, Kersting F, Just H, Heykants J, Meinertz T (1979) Lorcainide I. Saturable presystemic elimination. Clin Pharmacol Ther 26: 187–204
Kappenberger L, Fromer M, Shenasa M, Gloor H (1985) Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome. Clin Cardiol 8 (6): 321–326
Karagueuzian H, Fujimoto T, Katoh T, Peter T, McCullen A, Mandell W (1982) Suppression of ventricular arrhythmias by propafenone, a new antiarrhythmic agent during acute myocardial infarction in the conscious dog, a comparison study with lidocaine. Circulation 66 (6): 1190–1198
Karagueuzian H, Katoh T, McCullen A, Mandell W, Peter T (1984) Electrophysiologic and hemodynamic effects of propafenone, a new antiarrhythmic agent, on the anesthetized, closed chest dog: a comparative study with lidocaine. Am Heart J 107: 418 - 424
Kasper W, Meinertz T, Kersting F, Lollgen H, Lang K, Just H (1979) Electrophysiological actions of lorcainide in patients with cardiac disease. J Cardiovasc Pharmacol 1: 343–352
Kasper W, Treese N, Meinertz T, Jahnchen E, Pop T (1983) Electrophysiologic effects of lorcainide on the accessory pathway in the Wolff-Parkinson-White syndrome. Am J Cardiol 51 (10): 1618–1622
Kates R, Harrison D, Winkle R (1982) Metabolite accumulation during long term oral encainide administration. Pharmacol Ther 40: 427–432
Kates RE, Keefe DL, Winkle RA (1983) Lorcainide disposition. Kinetics in arrhythmia patients. Clin Pharmacol Ther 33: 28–34
Kates R, Yee YG, Winkle R (1985) Metabolite accumulation during chronic propafenone dosing in arrhythmia. Clin Pharmacol Ther 37: 610–614
Keefe D, Peters F, Winkle R (1982) Randomized double-blind placebo controlled cross-over trial, documenting oral lorcainide efficacy and suppression of symptomatic ventricular tachyarrhythmias. Am Heart J 103: 511–518
Keefe D, Kates R, Winkle R (1984) Comparative electrophysiology of lorcainide and norlorcainide in the dog. J Cardiovasc Pharmacol 6: 808–815
Kesteloot H, Stroobandt R (1977) Clinical experience with lorcainide (R15899), a new artiarrhythmic drug. Arch Int Pharmacodyn Ther 230 (2): 225–234
Kesteloot H, Stroobandt R (1979) Clinical experience of encainide (MJ9067): a new antiarrhythmic drug. Eur J Clin Pharmacol 16: 323–326
Kim S, Lai R, Ruffy R (1986) Treatment of paroxysmal reentrant supraventricular tachycardia with flecainide acetate. Am J Cardiol 58 (l): 80–85
Klotz U, Muller-Seydlitz P, Heimburg P (1978) Pharmacokinetics of lorcainide in man, a new antiarrhythmic agent. Clin Pharmacokinet 3: 407–418
Klotz U, Fischer C, Muller-Seydlitz P, Schultz J, Muller WA (1979 a) Alterations in the disposition of differently cleared drugs in patients with cirrhosis. Clin Pharmacol Ther 26: 221–227
Klotz U, Muller-Seydlitz P, Heimburg P (1979b) Disposition and antiarrhythmic effect of lorcainide. Int J Clin Pharmacol Biopharm 17: 152–158
Klotz U, Muller-Seydlitz P, Heimburg P (1979 c) Lorcainide infusion in the treatment of ventricular premature beats. Eur J Pharmacol 16: 1–6
Kunze K, Kuck K, Schluter M, Kuch B, Bleifeld W (1984) Electrophysiologic and clinical effects of intravenous and oral encainide in accessory atrioventricular pathway. Am J Cardiol 54 (3): 323–329
Lai R, Chapman P, Naccarrelli G, Troup P, Rinkenberger R, Dougherty A, Ruffy R (1985) Short and long term experience with flecainide acetate in the management of refractory life-threatening ventricular arrhythmias. J Am Coll Cardiol 6: 772–779
Lawson JW (1968) Antiarrhythmic activity of some isoquinoline derivatives determined by a rapid screening procedure in the mouse. J Pharmacol Exp Ther 160: 22–31
Leinonen H, Heikkila J, Sundberg S, Gordin A (1984) Lorcainide in the prophylaxis of ventricular arrhythmias in acute myocardial infarction. Ann Clin Res 16: 18–22
Lewis G, Holtzman J (1984) Interaction of flecainide with digoxin and propranolol. Am J Cardiol 53: 52–57b
Libersa CC, Lekieffre J, Caron J, Poirier J, Plady S, Kacei S, Kher A (1984) Electrophysiologic effects of encainide and its metabolite in 11 patients. Eur Heart J 5 (1): 290
Lindstrom T, Lacefield W, Whitaker G (1984) Metabolism of the antiarrhythmic agent, indecainide, in rats, dogs, and monkeys. Drug Metab Dispos 12 (6): 691–697
Livelli F, Ferrick K, Bigger JT, Reiffel J, Gliklich J, Coromilas J (1984) Mixed response to flecainide acetate (abstr). J Am Coll Cardiol 3:583 Lloyd E, Workman L, Commerford P, Mabin T (1981) Evaluation of lorcainide, a new antiarrhythmic agent. S Afr Med J 60: 929–931
Lui H, Lee G, Dietrich P, Low R, Mason D (1982) Flecainide induced QT prolongation and ventricular tachycardia. Am Heart J 103: 567–569
Manz M, Steinbeck G, Luderitz B (1985) Usefulness of programmed stimulation in predicting efficacy of propafenone in long term antiarrhythmic therapy for paroxysmal supraventricular tachycardia. Am J Cardiol 56 (10): 593–597
Mason J, Peters F (1981) Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia. Circulation 63: 670–675
McAllister C, Wolfenden H, Aslanian W, Woosley R, Wilkinson G (1986) Oxidative metabolism of encainide: polymorphism, pharmacokinetics and clinical considerations. Xenobiotica 16 (5): 483–490
McLeod A, Stiles G, Shand D (1984) Demonstration of beta adrenoreceptor blockade by propafenone hydrochloride: clinical pharmacologic, radioligand binding and adenylate cyclase activation studies. J Pharmacol Exp Ther 228 (2): 461–466
Mead R, Keefe D, Kates R, Winkle RA (1985) Chronic lorcainide therapy for symptomatic premature ventricular complexes: efficacy pharmacokinetics and evidence for nor-lorcainide antiarrhythmic effect. Am J Cardiol 55: 72–78
Meinertz T, Kasper W, Kersting F, Just H, Bechtold H, Jahnchen E (1979) Lorcainide II. Plasma concentration-effect relationship. Clin Pharmacol Ther 26: 196–204
Meinertz T, Kersting F, Kasper W, Just H, Bechtold H, Jahnchen E (1980) Hemodynamic effects of a single intravenous dose of lorcainide in patients with heart disease. Eur J Clin Pharmacol 18: 461–465
Meinertz T, Zehender M, Geibel A, Treese N, Hofmann T, Kasper W, Pop T (1984) Long term antiarrhythmic therapy with flecainide. Am J Cardiol 54: 91–96
Miura D, Wynn J, Keefe D, Laux B, Somberg J (1987) Antiarrhythmic effects of indecainide in drug resistant populations with ventricular tachycardia and programmed electrical stimulation. Am Heart J 113: 65–69
Morganroth J (1981) The efficacy and safety of lorcainide in the treatment of ventricular arrhythmias as assessed by frequent Holter monitoring. Prognosis in pharmacotherapy of life threatening arrhythmias. In: Jahnchen E, Meinertz TH, Towse G (eds) Royal Society of Medicine. International congress and symposium, series no 49. Academic, London, The Royal Society of Medicine, London
Morganroth J (1986 a) Encainide for ventricular arrhythmias: placebo controlled and standard comparison trials. Am J Cardiol 58:74–82C
Morganroth J, Pool P, Miller R, Hsu P, Lee I, Clark D (1986 b) Dose response range of encainide for benign and potential lethal ventricular arrhythmias. Am J Cardiol 57: 769–774
Morganroth J, Somberg JC, Pool P, Hsu P, Lee I, Durkee J (1986 c) Comparative study of encainide and quinidine in the treatment of ventricular arrhythmias. J Am Coll Cardiol 7: 9–16
Muhiddin K, Nathan AW, Hellestrand KJ, Banim SO, Camm AJ (1982) Ventricular tachycardia associated with flecainide. Lancet 2: 1220–1221
Musto B, D’onofrio A, Musto A, Cavallaro C, Marsico F (1986) Electrophysiologic effects in clinical efficacy of propafenone in pediatric patients with paroxysmal supraventricular re-entry tachycardia. G Ital Cardiol 16 (4): 336–343
Naccarelli G, Rinkenberg R, Dougherty A, Geibel R (1984) Use of encainide in treating atrial fibrillation in the Wolff-Parkinson-White syndrome. Circulation 70: 11–445 (abstr.)
Nathan A, Hellestrand K, Bexton R, Banim S, Spurrell R, Camm AJ (1984) Proar- rhythmic effects of the new antiarrhythmic agent, flecainide acetate. Am Heart J 107: 222–228
Neuss H (1985) Long term use of flecainide in patients with supraventricular tachy-cardia. Drugs 29 (Suppl 4): 21–25
Neuss H, Buss J, Schlepper M, Berthold R, Mitrovic V, Kramer A, Musial W (1983) Effect of flecainide on electrophysiological properties of accessory pathways in the Wolff-Parkinson-White syndrome. Eur Heart J 4 (5): 347–353
Nicholson M, Campbell RWF, Julian D (1982) Encainide in management of ventricular tachycardia. Aust NZ J Med 12: 313
Pentel P, Goldsmith S, Salerno D, Nasraway S, Palmer D (1986) Effect of hypertonic sodium bicarbonate on encainide overdose. Am J Cardiol 57: 878–880
Philipsborn G, Gries J, Hofmann H, Kreiskott H, Kretzschmar R, Muller D, Raschack M, Teschendorf H (1984) Pharmacology studies on propafenone and its main metabolite 5-hydroxy propafenone. Arzneimittelforschung 34 (2): 1489–1497
Platia E, Estes M, Heine D, Griffith L, Garan H, Ruskin J, Reid P (1985) Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachy-cardia. Am J Cardiol 55: 956–962
Podrid P, Lown B (1984) Propafenone, a new agent for ventricular arrhythmias. J Am Coll Cardiol 4: 117–125
Podrid P, Morganroth J (1985) Aggravation of arrhythmias during drug therapy; experience with flecainide acetate. Prac Cardiol ll(12): 55–70
Pop T, Treese N, Kana J, Meinertz T, Kasper W (1983) Effect of intravenous flecainide on atrial vulnerability in man. Klin Wochenschr 61 (12): 609–615
Prystowsky E, Klein G, Rinkenberger R, Heger J, Naccarelli G, Zipes D (1984) Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome. Circulation 69 (2): 278–287
Quart B, Gallo D, Sami M, Wood A (1986) Drug interaction studies and encainide use in renal and hepatic impairment. Am J Cardiol 58: 104–113c
Rehnqvist N, Ericsson C, Eriksson C, Olsson G, Svensson G (1984) Comparative investigation of the antiarrhythmic effect of propafenone (rytmonorn) and lido- caine in patients with ventricular arrhythmias during acute myocardial infarctions. Acta Med Scand 216: 525–530
Rinkenberger RL, Prystowsky E, Jackman W, Naccarelli G, Heger J, Zipes D (1982) Drug conversion of non-sustained ventricular tachycardia to sustained ventricular tachycardia during serial electrophysiologic studies: identification of drugs that exacerbate tachycardia and potential mechanisms. Am Heart J 103: 177–184
Roden D, Stots B, Reele S, Higgins S, Mayol R, Gammans R, Oates J, Woosley R (1980) Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics. ti Engl J Med 302: 877–882
Roden D, Wood A, Wilkinson G, Woosley R (1986) Disposition kinetics of encainide and metabolites. Am J Cardiol 58: 4–9c
Ruskin J, McGovern B, Garan H, DiMarco J, Kelly E (1983) Antiarrhythmic drugs: a possible cause of out-of-hospital cardiac arrest. N Engl J Med 309: 1302–1306
Rutsch W (1978) Influencing ventricular extra systoles with propafenone. Herz/Kreisl 10: 183–186
Saksena S, Rothbart S, Cappello G, Bernstein A, Somani P (1983) Clinical and electrophysiological effects of chronic lorcainide therapy in refractory ventricular tachycardia. J Am Coll Cardiol 2 (3): 538–544
Salerno D, Hodges M, Granrud G, Sharkey P (1983) Comparison of flecainide with quinidine for suppression of chronic stable ventricular ectopic depolarizations. Ann Int Med 98: 455–460
Salerno D, Granrud G, Sharkey P, Asinger R, Hodges M (1984) A controlled trial of propafenone for treatment of frequent and repetitive ventricular premature complexes. Am J Cardiol 53: 77–83
Salerno D, Fifield J, Krejci J, Larson T, Hodgess M (1986) Encainide induced hyperglycemia (abstr). Circulation 74 [suppl]:II: 104
Sami M, Mason J, Oh G, Harrison D (1979 a) Canine electrophysiology of encainide, a new antiarrhythmic drug. Am J Cardiol 43: 1149–1154
Sami M, Mason J, Peters F, Harrison D (1979b) Clinical electrophysiologic effects of encainide a newly developed antiarrhythmic agent. Am J Cardiol 44: 526–532
Sami M, Harrison D, Kreaemer H, Houston N, Shimasaki C, DeBusk R (1981) Antiarrhythmic efficacy of encainide and quinidine: validation of a model for drug assessment. Am J Cardiol 48: 147–156
Sami M, Derbekyan V, Lisbona R (1983) Hemodynamic effects of encainide in patients with ventricular arrhythmia and poor ventricular function. Am J Cardiol 52: 507–511
Samuelsson R, Harrison D (1981) Electrophysiologic evaluation of encainide with use of monophasic action potential recording. Am J Cardiol 48: 871–876
Sandusky G, Meyers D (1985) Toxicology of indecainide hydrochloric after intravenous administration to rats and dogs. Toxicol Lett 26 (2–3): 107–110
Schmid JR, Seebeck BD, Henrie CL, Banitt EH, Kvam DC (1975) Some antiarrhythmic actions of a new compound, R-818, in dogs and mice (abstr). Fed Proc 34: 775
Schwartz A, Shapiro W, Sauve M, Shen E, Bhandari A, Morady F, Scheinman M (1984) Adverse electrophysiologic effects of encainide in patients with bundle branch block (abstr). Clin Res 32: 1
Seipel L, Abendroth R, Breithardt G (1980) Electrophysiologic effects of flecainide (R- 818), in man (abstr). Circulation 62 (Suppl 3): III–153
Sellers TD, DiMarco JP (1985) Sinusoidal ventricular tachycardia associated with flecainide acetate. Chest 5: 647 - 649
Senges J, Rizos I, Brachmann J, Tian-Li G, Lengfelder RW, Kubler W (1982) Arrhyth- mogenic effect of toxic concentrations of the antiarrhythmic drug lorcainide on the isolated canine ventricle. J Pharmacol Exp Ther 223: 547–551
Serruys PW, Vanhaleweyk G, Van den brand M, Verdou P, Lubsen J, Hugenholtz PG (1983) Hemodynamic effects of intravenous flecainide acetate in patients with coronary artery disease. Br J Clin Pharmacol 16: 51–59
Shen EN, Sung RJ, Morady F, Schwartz AB, Scheinman MM, DiCarlo L, Shapiro W (1984) Electrophysiologic and hemodynamic effects of intravenous prapafenone in patients with recurrent ventricular tachycardia. J Am Coll Cardiol 3: 1291–1297
Shigenobu K, Tatsuno-Atoda H, Asano T, Kasuya Y (1980) Electrophysiologic effects of a new antiarrhythmic agent, lorcainide, on the isolated cardiac muscle fibers as compared with disopyramide. J Pharmacobiodyn 3: 677–685
Shita A, Bernard R, Mostinckx R, Debacker M (1981) Hemodynamic reactions after intravenous injections of lorcainide hydrochloride in acute myocardial infarction. Eur J Cardiol 12: 237–242
Siddoway L, McAllister CB, Wang T, Bergstrand R, Roden D, Wilkinson GR, Woos- ley R (1983) Polymorphic oxidative metabolism of propafenone in man. Circulation 68 (3): 64
Singh SN, DiBianco R, Kostroff L, Fletcher RD, Cockrell JL (1984) Lorcainide for high frequency ventricular arrhythmia: preliminary results of a short term double blind and placebo controlled crossover study and long term follow-up. Am J Cardiol 54: 22–28B
Solti F, Czako E, Szatmary L (1986) Electrophysiological characteristics of lorcainide, a new antiarrhythmic drug. Int J Clin Pharmacol Ther Toxicol 24: 26–29
Somani P (1980) Antiarrhythmic effects of flecainide. Clin Pharmacol Ther 27: 464–470
Somani P (1981) Pharmacokinetics of lorcainide, a new antiarrhythmic drug in patients with cardiac rhythm disorders. Am J Cardiol 48: 157–163
Somani P, di Giorgi S (1980) Resistant ventricular arrhythmias treated with lorcainide, a new antiarrhythmic drug. Chest 78 (4): 658–660
Somani P, Simon V, Gupka K, King P, Shapira R, Stochard H (1984 a) Lorcainide kinetics and protein binding in patients with end stage renal disease.:121–125
Somani P, Temesy-Armos P, Leighton R, Goodenday L, Fraker T (1984b) Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug. Am Heart J 108: 1443–1448
Somberg JC, Wellens H, Keren J, Miura DS (1982) A new animal model for the elec-trophysiologic testing of antiarrhythmic drugs. Fed Proc 41 (5): 1711
Somberg J, Butler, Flowers D, Keefe D, Torres V, Miura D (1984 a) Evaluation of lorcainide in patients with symptomatic ventricular tachycardia. Am J Cardiol 54: 43–48B
Somberg J, Butler B, Torres V, Flowers D, Tepper D, Keefe D, Miura D (1984b) Lor-cainide therapy for the high risk patient post myocardial infarction. Am J Cardiol 54: 37–42B
Somberg JC, Laux B, Wynn J, Keefe D, Miura D (1986) Lorcainide therapy in cardiac arrest population. Am Heart J 111: 648–653
Somberg JC, Tepper D, Sacker H, Schwartz J (1987) Chronic flecainide therapy selected by electrophysiology testing of intravenous flecainide. Am Heart I 114: 18–25
Soyka L (1986) Safety of encainide for the treatment of ventricular arrhythmias. Am J Cardiol 58: 96–103c
Soyza N, Terry L, Murphy M, Thompson C, Doherty J, Sakhaii M, Dinh H (1984) Effect of propafenone in patients with stable ventricular arrhythmias. Am Heart J 108: 285–289
Spivack C, Gottlieb S, Miura D, Somberg JC (1984) Flecainide toxicity. Am J Cardiol 53: 329–330
Stavens C, McGovern B, Garan H, Ruskin J (1985) Aggravation of electrically provoked ventricular tachycardia during treatment with propafenone. Am Heart J 110: 24–29
Steinberg M, Wiest S (1984) Electrophysiological studies of indecainide hydrochloride, a new antiarrhythmic agent, in canine cardiac tissue. J Cardiovasc Pharmacol 6 (4): 614–621
Strasburger J, Moak J, Smith R, McVey-Duncan P, Armstrong K, Garson A (1986) En- cainide for refractory supraventricular tachycardia in children. Am J Cardiol 58 (5): 49c–54c
Stroobandt R, Kesteloot H (1985) Efficacy and tolerance of intravenous lorcainide in patients with normal and impaired intra-ventricular conduction. Acta Cardiol (Brux) 40 (6): 637–648
Tjandramaga TB, Verbesselt R, Van-Hecken A, Mullie A, DeSchepper PJ (1982) Oral digoxin pharmacokinetics during multiple dose flecainide treatment. Arch Int Pharmacodyn 260: 302–303
Torres V, Flowers D, Somberg J (1985) The arrhythmogenicity of antiarrhythmic agents. Am Heart J 109 (5): 1090–1097
Tucker C, Winkle R, Peters F, Harrison DC (1982) Acute hemodynamic effects of intravenous encainide in patients with heart disease. Am Heart J 104 (2/l): 209–215
Vanhaleweyk G, Serruys P, Hugenholtz P (1984) Hemodynamic effects of encainide, flecainide, lorcainide and tocainide. Eur Heart J 5: 67–74
Vaughan Williams EM (1970) Classification of antiarrhythmic drugs. In: Sandoe et al. (eds) Cardiac arrhythmias. Astra, Sodertalge, Sweden, pp 449–473
Vaughan Williams EM (1984) A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 24: 129–147
Velebit V, Podrid P, Lown B, Cohen B, Graboys TB (1982) Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 65: 886–894
Verdouw, PD, Deckers JW, Conard JG (1979) Antiarrhythmic and hemodynamic actions of flecainide acetate (R-818) in ischemic porcine heart. J Cardiovasc Pharmacol 1: 473–486
Vlay S, Mallis G (1986) Intravenous and oral lorcainide: assessment of central nervous system toxicity and antiarrhythmic efficacy. Am Heart J 111: 452–455
Vlay SC, Mallis GI, Singh S, Cohn PF (1984) Comparison of lorcainide and quinidine in the treatment of ventricular ectopy. Chest 86: 80–83
Vorgeat A, Goy J, Maendly R, Kaufmann U, Grbic M, Sigwart U (1986) Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 58 (6): 496–498
Walker P, Papouchado M, James M, Clark L (1985) Pacing failure due to flecainide acetate. PACE 8: 900–902
Ward D, Jones S, Shinebourne E (1986) Use of flecainide acetate for refractory junctional tachycardia in children with the Wolff-Parkinson-White syndrome. Am J Cardiol 57 (10): 787–790
Wehr M, Noll B, Krappe J (1985) Flecainide induced aggravation of ventricular arrhythmias. Am J Cardiol 55: 1643–1644
Winkle R, Mason J, Griffin J, Ross D (1981a) Malignant ventricular tachyarrhythmias associated with the use of encainide. Am Heart J 102: 857–864
Winkle R, Peters F, Kates R, Tucker C, Harrison D (1981b) Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias. 64 (2): 290–296
Winkle R, Peters F, Kates R, Harrison D (1983) Possible contribution of encainide metabolites to the long term antiarrhythmic efficacy of encainide. Am J Cardiol 51: 1182–1188
Woestenborghs R, Michiels M, Heykants J (1979) Simultaneous gas chromotographic determination of lorcainide hydrochloride and three of its principle metabolites in biological samples. J Chromotogr 164: 169–176
Woosley R, Roden D, Guizhu D, Wang T, Altenbern D, Oates J, Wilkinson G (1986) Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Clin Pharmacol Ther 39: 282–289
Wynn J, Fingerhood M, Keefe D, Maza S, Miura D, Somberg JC (1986) Refractory ventricular tachycardia with flecainide. Am Heart J 112 (1): 174–175
Xhonneux R, Remeysm P (1975) Effectiveness of R-15889 (lorcainide) and ouabain induced ventricular arrhythmias in anesthetized dogs. Janssen Research Technical Report, Janssen Pharmaceutica, Belgium, N9969
Yee Y, Kates R (1981) High performance liquid chromotographic analysis of lorcainide and its active metabolite, nor-lorcainide in plasma. J Chromotogr 223: 454–459
Zeiler R, Gough W, El-Sherif N (1984) Electrophysiologic effects of propefanone on canine ischemic cardiac cells. Am J Cardiol 54: 424–429
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Somberg, J.C. (1989). Clinical Use of Class Ic Antiarrhythmic Drugs. In: Vaughan Williams, E.M. (eds) Antiarrhythmic Drugs. Handbook of Experimental Pharmacology, vol 89. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73666-7_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-73666-7_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73668-1
Online ISBN: 978-3-642-73666-7
eBook Packages: Springer Book Archive